Profile image
浏览次数

现在:
最近一小时:
最近24小时:
浏览总量:
US Clinical Laboratory Testing Market Witnessing Significant Consolidation
Tuesday, February 21, 2017 23:35
% of readers think this story is Fact. Add your two cents.
0

“Various players entering into strategic alliances for expanding their footprints in the US Clinical Laboratory Testing market” says RNCOS

 

Clinical Laboratory provides laboratory information and services needed for the diagnosis and treatment of disease. The laboratory tests performed by clinical laboratory scientists include- the detection of the abnormal cells that cause leukemia, the analysis of cardiac enzyme activity released during a heart attack, the identification of the type of bacteria causing an infection, the detection of DNA markers for genetic diseases and many more.

 

According to a new research report by RNCOS entitled, “US Clinical Laboratory Testing Market by Type of Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, Physician, Independent), & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast to 2022” the prevailing medical laboratory business model, particularly in the US, suffers from too much fragmentation, redundancy and excess capacity. Such a model has competitive disadvantages and is no longer adequate in the new reality of the need for much greater cost containment and increased competition. Laboratories should therefore seek to cooperate, consolidate to enhance efficiency and reduce costs.

 

To overcome this issue, the US clinical lab industry has experienced significant consolidation in the last three years, with Quest, LabCorp, Sonic and Solstas Lab Partners accounting for majority of deals. Even though M&A activity and valuations reduced in 2009 (due to recessionary impacts), large commercial labs continued to compete for highly-attractive strategic acquisitions in the succeeding years.

 

Moreover, the sector has attracted private equity investors that have established or are seeking platform acquisitions. M&A strategies with commercial labs focus on smaller, strategic acquisitions in high-growth esoteric testing segments. In future, M&A activity is anticipated to continue, as LabCorp and Quest have shown a strong interest in acquisitions. These two will face competition from Sonic, Bio-Reference, regional labs, and private equity investors.

 

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM888.htm

 

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

 

ABOUT RNCOS

 

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

今日头条
最新故事

Register

Newsletter

Email this story
Share This Story:
Print this story
Email this story
Digg
Reddit
StumbleUpon
Share on Tumblr
GET ALERTS:

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.